VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
December 19, 2017 08:00 ET
|
VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
ISR Projects Continued Growth Propelling the CRO Market Forward
February 02, 2016 11:56 ET
|
Industry Standard Research
CARY, NC--(Marketwired - February 02, 2016) - Industry Standard Research (ISR) today announced a new addition to its Market Analysis suite of reports. The "2016 Edition of the CRO Market Size...
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
June 09, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 9, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing...
Accenture, ICON Among Providers Shortlisted in ISR's 7th Annual CRO Quality Benchmarking Study
May 06, 2015 11:49 ET
|
Industry Standard Research
CARY, NC--(Marketwired - May 06, 2015) - Industry Standard Research (ISR) has announced the availability of its 7th annual CRO Quality Benchmarking series with the release of its "CRO Quality...
Boardroom Radio Interview with Mesoblast Chief Executive
February 02, 2014 20:06 ET
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...
After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
December 05, 2013 09:15 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 5, 2013) - Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced,...
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
November 05, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have...
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
November 04, 2013 09:56 ET
|
Nuvilex, Inc.
SILVER SPRING, MD--(Marketwired - Nov 4, 2013) - Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...
Nuvilex, Inc. Enters Most Important Step of Phase III Trials Outside of Patient Enrollment
October 01, 2013 08:45 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Oct 1, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future...
Nuvilex, Inc. Names Two Significant Partners on Its Way to Phase 3 Clinical Trials
September 19, 2013 09:00 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made another subtle but significant move this week that seems to signal the company is in "go-mode" on its future Phase III...